Compare SMID & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | TLSA |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 155.3M |
| IPO Year | 1996 | 2017 |
| Metric | SMID | TLSA |
|---|---|---|
| Price | $30.94 | $0.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.6K | ★ 266.6K |
| Earning Date | 04-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $121.12 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $0.87 |
| 52 Week High | $43.62 | $2.60 |
| Indicator | SMID | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 36.84 |
| Support Level | $28.01 | N/A |
| Resistance Level | $31.21 | $1.45 |
| Average True Range (ATR) | 1.11 | 0.12 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 69.13 | 10.55 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.